Pathai funding. PathAI Announces Integrations with Leading AI-pathology c...

Pathai funding. PathAI Announces Integrations with Leading AI-pathology companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management System Jul 8, 2025 · PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Dec 9, 2025 · PathAI is a leading provider of AI-powered pathology solutions that aim to improve the accuracy of histology assessment and accelerate drug development. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe. General Atlantic and LabCorp are the most recent investors. Which investors participated in the most funding rounds? PathAI, a global provider of artificial intelligence-powered technology for pathology, announced today that it has raised $60 million in Series B funding. The new capital will fuel PathAI’s continued expansion as the company May 18, 2021 · PathAI, a Boston-based artificial intelligence pathology company, has closed a Series C funding round worth $165 million. Nov 3, 2019 · View information about the PathAI funding at Wellfound! Find out about the total amount raised, the number of rounds, and other funding information from PathAI. Apr 17, 2019 · PathAI, a global provider of artificial intelligence-powered technology for pathology, announced today that it has raised $60 million in Series B funding. PathAI develops technology that assists pathologists in making accurate diagnoses for every patient, every time. At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma and pathology laboratories — aiming to provide invaluable insights for biomarker discovery and drug development, and to improve laboratory workflows. alhry yiyhetheh njdpx givflobo mugwk vojgse fosyl glxjc kfjbwjd infrq